ISIS Pharmaceuticals, Inc. Share Price Nasdaq
Stocks
US4643301090
Biotechnology & Medical Research
| Market Cap | 12.54B 10.98B 10.14B 9.47B 17.75B 1,187B 17.92B 121B 46.86B 583B 47.08B 46.06B 2,026B | P/E 2026 * |
-21x | P/E 2027 * | -58.8x |
|---|---|---|---|---|---|
| Enterprise Value | 12.32B 10.78B 9.97B 9.3B 17.44B 1,167B 17.61B 119B 46.04B 572B 46.26B 45.26B 1,991B | EV / Sales 2026 * |
13.8x | EV / Sales 2027 * | 8.31x |
| Free-Float |
99.08% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: ISIS Pharmaceuticals, Inc.
| 1 day | +1.33% |
| Manager | Title | Age | Since |
|---|---|---|---|
D. Walke
IRC | Investor Relations Contact | 60 | 30/06/2012 |
Brett Monia
CEO | Chief Executive Officer | 64 | 31/12/2019 |
Elizabeth Hougen
DFI | Director of Finance/CFO | 64 | 30/04/2000 |
| Director | Title | Age | Since |
|---|---|---|---|
Joseph Klein
BRD | Director/Board Member | 64 | 12/12/2005 |
| Director/Board Member | 73 | 30/04/2002 | |
Brett Monia
BRD | Director/Board Member | 64 | 24/03/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.33% | +2.73% | - | - | 12.25B | |
| +0.34% | +2.06% | -10.67% | -5.26% | 43.13B | |
| +1.73% | +7.76% | +318.08% | +543.17% | 34.65B | |
| +0.61% | +2.77% | +10.00% | +46.44% | 30.03B | |
| +0.02% | -7.52% | +8.45% | -21.52% | 28B | |
| -1.06% | -2.60% | +9.08% | +21.51% | 24.45B | |
| -1.23% | +4.56% | - | - | 14.34B | |
| -0.99% | -2.50% | +47.29% | +106.70% | 13.14B | |
| +1.54% | -0.94% | +6.69% | +8.40% | 12.53B | |
| -3.61% | -3.73% | -3.93% | -38.14% | 11.18B | |
| Average | -0.13% | +0.32% | +48.12% | +82.66% | 23.5B | |
| Weighted average by Cap. | +0.14% | +1.03% | +60.79% | +106.50% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 890M 779M 720M 672M 1.26B 84.25B 1.27B 8.56B 3.32B 41.34B 3.34B 3.27B 144B | 1.49B 1.31B 1.21B 1.13B 2.11B 141B 2.13B 14.37B 5.58B 69.39B 5.61B 5.49B 241B |
| Net income | -595M -521M -481M -449M -842M -56.34B -851M -5.72B -2.22B -27.65B -2.23B -2.19B -96.15B | -216M -189M -175M -163M -306M -20.44B -309M -2.08B -807M -10.03B -810M -793M -34.88B |
| Net Debt | -219M -192M -177M -165M -310M -20.74B -313M -2.11B -819M -10.18B -823M -805M -35.4B | -122M -107M -98.53M -91.97M -172M -11.53B -174M -1.17B -455M -5.66B -457M -447M -19.69B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
